Company — Spark Therapeutics
Focused on developing curative, one-time gene therapy products including lead gene therapy candidate, for RPE65-related blindness. (NASDAQ: ONCE) (Acquired by Roche)
Focused on developing curative, one-time gene therapy products including lead gene therapy candidate, for RPE65-related blindness. (NASDAQ: ONCE) (Acquired by Roche)